Chile OKs Orladeyo to prevent HAE attacks in patients 12 and older
Authorities in Chile have approved Orladeyo (berotralstat) to prevent swelling attacks in hereditary angioedema (HAE) patients 12 and older, marking the therapy’s first marketing authorization in a Latin American country. The preventive, or prophylactic, oral therapy from BioCryst Pharmaceuticals holds similar approvals in the U.S.,…